Preventing metastasis and recurrence after cancer treatment remains a challenge. Extracellular vesicles (EVs) have long garnered attention as tools for vaccination. To develop high-performance vaccines, there has been an ongoing search for high-performance miRNAs and high-performance EVs as resources. In recent years, stemness-high cells have been reported to represent valuable resources for EVs, offering a level of performance not previously achieved. A differential miRNA analysis was performed between metastasis-suppressive EVs and metastasis-promoting EVs to predict miRNAs specific to metastasis regulation. These newly identified miRNAs were expected to show good performance in metastasis suppression. It is noticeable that these miRNAs seem to be categorized differently from the cancer-associated miRNAs that have been extensively studied to date. In order to further develop vaccine therapy, it is widely recognized that continuing to explore methods for further enhancing the metastasis-suppressive potential of EVs and mRNAs is a fundamental and urgent task. Significant progress has been made through the discovery of stemness-high cells as new EV resources and the results of miRNA exploration focused on metastasis regulation. This review aims to address current challenges by presenting relevant, up-to-date information and providing insights that may lead to new discoveries.
预防癌症治疗后的转移与复发仍是临床面临的重大挑战。细胞外囊泡作为疫苗载体工具长期受到学界关注。为开发高效能疫苗，研究者持续探寻可作为资源的高性能微小核糖核酸与高性能细胞外囊泡。近年研究表明，高干性细胞可作为极具价值的细胞外囊泡来源，其性能表现达到前所未有的水平。本研究通过对比分析转移抑制型与转移促进型细胞外囊泡的微小核糖核酸表达谱，成功预测出具有转移调控特异性的微小核糖核酸。这些新发现的微小核糖核酸在转移抑制方面展现出优异性能。值得注意的是，这些微小核糖核酸的分类特征明显区别于当前已被广泛研究的癌症相关微小核糖核酸。为推进疫苗疗法的进一步发展，学界普遍认为持续探索增强细胞外囊泡与信使核糖核酸转移抑制潜能的方法是一项基础且紧迫的任务。通过发现高干性细胞作为新型细胞外囊泡资源，以及聚焦转移调控的微小核糖核酸探索成果，该领域已取得显著进展。本综述旨在通过呈现相关前沿信息并提供可能引领新发现的见解，以应对当前面临的挑战。
肿瘤(癌症)患者之家